吸入性环索奈德对比布地奈德治疗轻中度哮喘的安全性评价

Evaluation on Safety of Inhaled Ciclesonide versus Budesonide in Treating Mild-Moderate Asthma

目的比较吸入性环索奈德与布地奈德治疗轻中度哮喘的安全性。方法采用cot-hrane系统评价方法双人进行资料提取、分析、评价,筛选出符合评价标准的文献,并使用RevMan 5.0软件进行Meta分析。结果共纳入9项研究,合计3 094例轻中度哮喘患者。分析结果显示,环索奈德与布地奈德治疗轻中度哮喘的不良事件总发生例数、加重哮喘、上呼吸道感染、流感综合征、鼻炎、发声异常、咽炎、头痛、支气管炙、口干、乏力、失眠、关节疼痛、皮肤瘙痒、转氨酶升高、咳嗽等比较,均无统计学意义。

Objective To compare the safety of inhaled ciclesonide and budesonide in treating mild- moderate asthma. Methods The Cochrane systematic review method was adopted to conduct the data extract, analysis and evaluation for screening out the literatures ac- cording to the evaluation criteria by two persons. The meta- analysis was performed by using RevMan 5.0 software. Results Nine ran- domized controlled trials（RCTs） involving 3094 cases of mild- moderate asthma were included. The Meta-Analysis results showed that there were no statistical differences between ciclesonide and budesonide in the total occurrence cases of adverse events, asthma aggrava- tion, upper respiratory tract infections, flu syndrome, rhinitis, heterophonia, pharyngitis, headache, bronchitis, dry mouth, hypodynamia, agrypni- a, arthrosis pain, skin itch, high aminotransferase, cough, et al. Conclusion The safety of inhaled ciclesonide and budesonide in treating mild- moderate asthma is similar.